Cancer remains one of the leading causes of morbidity and mortality worldwide, despite significant advances in molecular biology, targeted therapy, and ...

Fact check - There is no link between the discovery of cancer treatments and vaccines and the US leaving the WHO.

Revolution Medicines, Inc. (NASDAQ:RVMD) is one of the best cancer stocks to invest in now. On February 26, Revolution Medicines, Inc. (NASDAQ:RVMD) CEO Mark A. Goldsmith reiterated that the company ...

BioNTech and partner DualityBio are accelerating the development of their B7-H3 antibody-drug conjugate into a phase 3 trial for metastatic castration-resistant prostate cancer (mCRPC). | BioNTech and ...

Rare Disease Day is held on the last day of February to raise awareness for rare diseases and address drug development ...

Hernexeos is the second drug to secure an FDA approval under the agency’s priority voucher scheme, following in the footsteps of USAntibiotics’ Augmentin XR, which was granted the ticket in December ...

A one‑year course of T‑DM1 offers excellent cancer‑free survival for early HER2‑positive breast cancer, with far less nerve ...

Thanks to modern therapies, a cancer diagnosis is no longer an automatic death sentence. But many patients still suffer from ...

The bispecific ADC izalontamab brengitecan improved survival for patients with metastatic triple-negative breast cancer in a ...

CEOCFO interviews NanOlogy, LLC CEO David J. Arthur on Solving Toxicity & Bioavailability Problems when Treating ...

FCS Physicians Present Novel Clinical Trial Findings in Prostate and Urothelial Cancers at the ASCO 2026 Genitourinary ...

Astellas Pharma has agreed to co-develop and co-commercialize Vir Biotechnology’s prostate cancer candidate VIR-5500 through a collaboration that could generate more than $1.7 billion for the San ...